Taigen Biopharmaceutica Cash Flow From Operations vs. Revenue

4157 Stock  TWD 11.45  0.35  2.97%   
Based on the key profitability measurements obtained from Taigen Biopharmaceutica's financial statements, Taigen Biopharmaceuticals Holdings may not be well positioned to generate adequate gross income at the moment. It has a very high risk of underperforming in January. Profitability indicators assess Taigen Biopharmaceutica's ability to earn profits and add value for shareholders.
For Taigen Biopharmaceutica profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Taigen Biopharmaceutica to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Taigen Biopharmaceuticals Holdings utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Taigen Biopharmaceutica's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Taigen Biopharmaceuticals Holdings over time as well as its relative position and ranking within its peers.
  
Check out Trending Equities.
Please note, there is a significant difference between Taigen Biopharmaceutica's value and its price as these two are different measures arrived at by different means. Investors typically determine if Taigen Biopharmaceutica is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Taigen Biopharmaceutica's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Taigen Biopharmaceutica Revenue vs. Cash Flow From Operations Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Taigen Biopharmaceutica's current stock value. Our valuation model uses many indicators to compare Taigen Biopharmaceutica value to that of its competitors to determine the firm's financial worth.
Taigen Biopharmaceuticals Holdings is number one stock in cash flow from operations category among its peers. It is rated second in revenue category among its peers totaling about  2.06  of Revenue per Cash Flow From Operations. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Taigen Biopharmaceutica's earnings, one of the primary drivers of an investment's value.

Taigen Revenue vs. Cash Flow From Operations

Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.

Taigen Biopharmaceutica

Operating Cash Flow

 = 

EBITDA

-

Taxes

 = 
629.07 M
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.

Taigen Biopharmaceutica

Revenue

 = 

Money Received

-

Discounts and Returns

 = 
1.29 B
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.

Taigen Revenue vs Competition

Taigen Biopharmaceuticals Holdings is rated second in revenue category among its peers. Market size based on revenue of Health Care industry is presently estimated at about 9.37 Billion. Taigen Biopharmaceutica retains roughly 1.29 Billion in revenue claiming about 14% of equities under Health Care industry.

Taigen Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Taigen Biopharmaceutica. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Taigen Biopharmaceutica position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Taigen Biopharmaceutica's important profitability drivers and their relationship over time.

Use Taigen Biopharmaceutica in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Taigen Biopharmaceutica position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Taigen Biopharmaceutica will appreciate offsetting losses from the drop in the long position's value.

Taigen Biopharmaceutica Pair Trading

Taigen Biopharmaceuticals Holdings Pair Trading Analysis

The ability to find closely correlated positions to Taigen Biopharmaceutica could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Taigen Biopharmaceutica when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Taigen Biopharmaceutica - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Taigen Biopharmaceuticals Holdings to buy it.
The correlation of Taigen Biopharmaceutica is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Taigen Biopharmaceutica moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Taigen Biopharmaceutica moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Taigen Biopharmaceutica can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Taigen Biopharmaceutica position

In addition to having Taigen Biopharmaceutica in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Climate Change Thematic Idea Now

Climate Change
Climate Change Theme
Large and medium sized entities that are committing to fully or partially replace some traditional services or products with renewables sources of energy in order to combat global climate change. The Climate Change theme has 41 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Climate Change Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Taigen Stock Analysis

When running Taigen Biopharmaceutica's price analysis, check to measure Taigen Biopharmaceutica's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Taigen Biopharmaceutica is operating at the current time. Most of Taigen Biopharmaceutica's value examination focuses on studying past and present price action to predict the probability of Taigen Biopharmaceutica's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Taigen Biopharmaceutica's price. Additionally, you may evaluate how the addition of Taigen Biopharmaceutica to your portfolios can decrease your overall portfolio volatility.